Antisecretory factor AF-16 improves vascular access to a rat mammary tumour

APMIS. 2020 May;128(5):387-389. doi: 10.1111/apm.13036.

Abstract

Tumor tissue often has an insufficient nutritional supply, in part due to compression of the vascular network from an increased interstitial fluid pressure. We have shown that the antisecretory factor peptide AF-16 can reduce this pressure in experimental rat breast tumors. In this work we studied if AF-16 administration opened up to an increased vascular volume in these tumors. Sprague-Dawley rats were given dimethylbenxanthracene and developed mammary tumors which were studied. Evans Blue was used as an intravascular volume indicator. Under anesthesia the rats were given AF-16 or solvent intranasally, and Evans Blue was injected i.v. 45 min later. Tumors and various organs were dissected and Evans Blue was extracted and colorimetrically quantified. Tumors had a significantly higher vascular volume after AF-16 administration as compared to other organs. Liver and renal vascular volumes were also increased but to a lesser degree than in the tumors. The results indicate that AF16 could be a candidate for increasing vascular access for chemotherapy in cancer therapy.

Keywords: Antisecretory Factor; DMBA tumor; evans blue; interstitial fluid pressure; rat; vascular volume.

MeSH terms

  • Animals
  • Female
  • Kidney / pathology
  • Liver / pathology
  • Mammary Neoplasms, Experimental / blood supply*
  • Mammary Neoplasms, Experimental / pathology*
  • Neuropeptides
  • Peptides / administration & dosage*
  • Rats
  • Rats, Sprague-Dawley
  • Vascular Patency / drug effects*

Substances

  • Neuropeptides
  • Peptides
  • antisecretory factor
  • peptide AF-16